Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

2007 ◽  
Vol 112 (1) ◽  
pp. 203-213 ◽  
Author(s):  
Brigitte Mlineritsch ◽  
Christoph Tausch ◽  
Christian Singer ◽  
Gero Luschin-Ebengreuth ◽  
Raimund Jakesz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Cancer Patients ◽  
Phase Ii Trial ◽  
Systemic Treatment ◽  
Study Group ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive ◽  
Cancer Study Group ◽  
Post Menopausal

Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – A phase II trial

2014 ◽  
Vol 50 (13) ◽  
pp. 2190-2200 ◽  
Author(s):  
Duveken B.Y. Fontein ◽  
Ayoub Charehbili ◽  
Johan W.R. Nortier ◽  
Elma Meershoek-Klein Kranenbarg ◽  
Judith R. Kroep ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Breast Cancer Patients ◽  
Neoadjuvant Endocrine Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

2006 ◽  
Vol 24 (22) ◽  
pp. 3623-3628 ◽  
Author(s):  
Alberto Bottini ◽  
Daniele Generali ◽  
Maria Pia Brizzi ◽  
Stephen B. Fox ◽  
Alessandra Bersiga ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Systemic Treatment ◽  
Treated Group ◽  
Oral Cyclophosphamide ◽  
Breast Cancer Patients ◽  
Randomized Phase Ii ◽  
To Receive

Purpose To investigate the activity of letrozole plus/minus oral metronomic cyclophophamide as primary systemic treatment (PST) in elderly breast cancer patients. Methods One hundred fourteen consecutive elderly women with T2-4 N0-1 and estrogen receptor–positive breast cancer were randomly assigned to primary letrozole therapy (2.5 mg daily for 6 months) or a combination of letrozole plus oral cyclophosphamide (50 mg/daily for 6 months) in an open-labeled, randomized phase II trial. Tumor response was assessed clinically, and tumor Ki67 index and vascular endothelial growth factor (VEGF) -A levels were measured before and after treatment. Results Overall response rate was 71.9% (95% CI, 60.0 to 83.8) in the 57 patients randomly assigned to receive primary letrozole and 87.7% (95% CI, 78.6 to 96.2) in the 57 patients randomly assigned to receive letrozole plus cyclophosphamide. The difference in activity between treatment arms was predominantly confined to patients with ductal histology. There was a significantly greater suppression of Ki67 and VEGF-A expression in the letrozole/cyclophosphamide-treated group than in the letrozole-treated group, leading to lower Ki67 and VEGF expression at post-treatment residual histology (P = .03 and P = .002, respectively). Conclusion Both letrozole and letrozole plus cyclophosphamide treatments appeared active as PST in elderly breast cancer patients. Metronomic scheduling of cyclophosphamide may have an antiangiogenetic effect and the combination of letrozole plus cyclophosphamide warrants testing in a randomized phase III trial.

Sign in / Sign up

Export Citation Format

Share Document